| Title: |
The role of galactomannan test results in the diagnosis of pediatric invasive aspergillosis. |
| Authors: |
Özen, Seval; Özdemir, Halil; Evren, Ebru; Taşkın, Esra Çakmak; Arga, Gül; Konca, Hatice Kübra; Çakmaklı, Hasan Fatih; Haskoloğlu, Şule; Okulu, Emel; Dinçaslan, Handan; İnce, Elif; İleri, Talia; Taçyıldız, Nurdan; Doğu, Figen; Us, Ebru; Karahan, Zeynep Ceren; Fitöz, Suat; Kendirli, Tanıl; Kuloğlu, Zarife; Tutar, Ercan |
| Source: |
Infectious Diseases; Apr 2022, Vol. 54 Issue 4, p269-276, 8p, 1 Diagram, 4 Charts, 3 Graphs |
| Subject Terms: |
Pulmonary aspergillosis; Aspergillosis; Invasive diagnosis; Child patients; Odds ratio |
| Abstract: |
Invasive aspergillosis (IA) is an important cause of morbidity and mortality in immunosuppressed children. Early detection of the infection can improve prognosis in this patient population. To investigate the utility of Aspergillus galactomannan antigen assay (GM-EIA) as a diagnostic tool for IA in at-risk paediatric patients. For the study, 659 GM-EIA results from 59 patients diagnosed with IA and 3368 GM-EIA results from 351 subjects without evidence for IA (controls) were reviewed retrospectively. Three cut-off values (i.e. ≥0.5, ≥1, ≥1.5) were specified to determine GM-EIA positivity. The median age was 6.3 years for boys and 14.5 years for girls. There was a significant difference between the girls and boys in terms of age (p < 0.01). For proven/probable/possible IA patients, sensitivity of 67.8% and specificity of 59.8% were detected when the ≥0.5 cut-off value was used for GM-EIA-positivity. The specificity increased to 80% at the cut-off of ≥1 and to 88% at the cut-off of ≥1.5. False positivity rates were 9.14, 3, and 1.45% at the ≥0.5, ≥1 and ≥1.5 cut-offs respectively. In the proven/probable IA group, sensitivity and negative predictive values were 86.9 and 97.2% at the ≥0.5 cut-off, 85.7 and 97.9%, at the ≥1 cut-off and 84.2 and 98.1% at ≥1.5 cut-off respectively. The positive likelihood ratio was 7.57 and the odds ratio was 42.67 at ≥1.5 cut-off. The GM-EIA may be used for both screening and diagnostic purposes in paediatric patients using a cut-off value of ≥1.5 for GM-EIA positivity. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Infectious Diseases is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |